Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior
This research is being done to find out if an evaluation of leukemia stem cells can guide further treatment for acute myelogenous leukemia (AML) and improve patient outcomes. Specifically, to determine IF a new experimental lab test to look for leukemia stem cells, can predict whether patients with AML will benefit from stem cell transplant (SCT) given earlier in treatment. This research study proposes to test patients for evidence of leukemia stem cells at the time of first remission and base further therapy on whether or not leukemia stem cells are present.
Age 18 years to 75 yearsNew diagnosis of AML, other than APL or poor-risk AMLthat has been treated with induction therapy in the last four weeks
Patients without detectable leukemia stem cells by flow cytometry, will be assigned to standard cytarabine-based chemotherapy as per institutional standards. Patients with detectable leukemia stem cells by flow cytometry will be randomized to either standard cytarabine-based consolidation therapy or allogeneic stem cell transplant, per institutional standards. Patients will receive the transplant from a related donor who is at least a haploidentical match. The choice of the optimal donor will use institutional priority extant at the time. Patients eligible for myeloablative conditioning will be prioritized to receive it; patients not eligible for myeloablative conditioning will receive non-myeloablative conditioning.
08/29/2014 04:02 AM